MedTrace Logo

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

NCT02157922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-04-19

No results posted yet for this study

Summary

The purpose of the study is assessment of efficacy and safety of OligoG as a dry powder formulation, in adult subjects with cystic fibrosis.

Conditions

Interventions

DRUG

alginate oligosaccharide

Inhalation

Sponsors & Collaborators

  • Eurostars

    collaborator OTHER

  • Smerud Medical Research International AS

    collaborator OTHER

  • AlgiPharma AS

    lead INDUSTRY

Principal Investigators

  • Tacjana Pressler, PhD MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-01-31
Completion
2017-09-30

Countries

  • Denmark
  • Germany
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02157922 on ClinicalTrials.gov